IMPAACT 2019 - Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Disperible and Immediate Release Tablets in HIV-1-Infected Children less than 12 years of Age

Grant

Total Award Amount

  • 111695.00
  • Direct Costs

  • 85919.00
  • Sponsor Award Id

  • LAB 13
  • Contributor

  • Edward Acosta Pharm.D.   Principal Investigator